Recipharm and ProductLife Group join forces to accelerate biologic development projects

Published: 14-May-2025

The companies will provide customers with integrated development, manufacturing, regulatory and market expertise for an end-to-end service

Contract development and manufacturing organisation (CDMO) Recipharm has teamed up with ProductLife Group to support pharmaceutical companies in accelerating time to clinical trials.

By combining Recipharm's fully integrated small molecule, biologics and advanced therapy development and manufacturing capabilities with PLG's product development and regulatory expertise, the companies will offer biopharma players support from early-stage development to approval.

Together, the companies plan to accelerate time to clinical trials and market approval, while reducing supply chain, compliance and regulatory challenges during product development.

For Recipharm’s customers, the partnership offers immediate access to PLG’s product development expertise as well as their global regulatory affairs, pharmacovigilance and market access experience.

With PLG integrated into Recipharm’s service offering, pharma and biotech companies can now align product development, regulatory and market access in the early stages while maintaining both control and foresight throughout scale-up and manufacturing.

For PLG’s clients, the collaboration opens access to Recipharm’s manufacturing infrastructure, including integrated and intelligent development, manufacturing support for faster and more cost-effective development, and predictive models for biologics production and release, offering a high-value solution tailored to global needs.

"This partnership brings together Recipharm’s development and manufacturing expertise, with PLG’s 2,000 regulatory experts, operating across 150 countries," explained Greg Behar, Recipharm’s CEO.

"By integrating scientific, regulatory, operational and commercial strategy from the outset we help our customers move faster, avoid costly delays and build confidence that their product submissions will meet and exceed, agency requirements, for critical medicines worldwide. "

"As regulatory complexity grows, our clients need integrated solutions that connect strategy and execution. With Recipharm’s 700 product development experts and over 400 projects delivered annually, this partnership allows us to embed regulatory thinking directly into product development and operational planning," added Xavier Duburcq, PLG’s CEO. 

 

You may also like